HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lange, R. C. Articles by Harder, H. C. Search for Related Content PubMed PubMed Citation Articles by Lange, R. C. Articles by Harder, H. C.

The Antitumor Agent CIS-Pt(NH₃)₂Cl₂: Distribution Studies and Dose Calculations for ^193mPt and ^195mPt

Section of Nuclear Medicine, Yale University School of Medicine, New Haven, Connecticut

Correspondence: For reprints contact: Robert C. Lange, Section of Nuclear Medicine, Yale University School of Medicine, New Haven, Conn. 06510.

ABSTRACT

The radioisotopes of platinum ^193mPt and ^195mPt were produced and compared as radiolabels for the antitumor compound cis-Pt (NH₃)₂Cl2. On the basis of physical characteristics, ^195mPt was the radioisotope of choice. When radiolabeled cis-Pt(NH₃)₂Cl₂ (with carrier) was injected into mice bearing sarcoma 180, the tumor/blood ratio of radioactivity varied from 1:3 to 2:0 (4 hr to 5 days after injection). Organ distribution in tumor-bearing mice was similar to that previously noted in control mice. Plasma disappearance data in two patients revealed an initial rapid fall in radioactivity following intravenous injection and then a slower phase. In the two cases, it was estimated that 60–70% of the radiolabel was retained after two days. Most excretion of radioactivity was through the urine.

This article has been cited by other articles:

				M. F. Dominguez, R. I. R. Macias, I. Izco-Basurko, A. de la Fuente, M. J. Pascual, J. M. Criado, M. J. Monte, J. Yajeya, and J. J. G. Marin Low in Vivo Toxicity of a Novel Cisplatin-Ursodeoxycholic Derivative (Bamet-UD2) with Enhanced Cytostatic Activity versus Liver Tumors J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1106 - 1112. [Abstract] [Full Text]

				W. Wolf, J. Shani, R. Dahalan, R. Parti, Shaharuddin bin Mohd, and T. K. Kawada A New Approach to Organ Pharmacokinetics Using Noninvasive Radionuclide Measurement Methods Journal of Pharmacy Practice, January 1, 1989; 2(3): 196 - 199. [Abstract] [PDF]